Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
Europe
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Gallimycin
1. 643-22-1
2. Abboticine
3. Bristamycin
4. Erypar
5. Dowmycin E
6. Wyamycin S
7. Pfizer-e
8. Erythrocin Stearate
9. Gallimycin
10. Sk-erythromycin
11. Erythromycin Octadecanoate (salt)
12. Nsc-756747
13. Nci-c55674
14. Lxw024x05m
15. Eratrex
16. Meberyt
17. Qidmycin
18. Ethril
19. Ethril 250
20. Ethril 500
21. Erythromycin Stearate (salt)
22. Erythromycin, Stearate (salt)
23. Erythromycin Steraric Acid Salt
24. Ccris 1504
25. Oe 7
26. Hsdb 4178
27. Einecs 211-396-1
28. Unii-lxw024x05m
29. Stearic Acid, Compd. With Erythromycin (1:1)
30. Bristamycin (tn)
31. Octadecanoic Acid, Compd. With Erythromycin (1:1)
32. Erythromycini Stearas
33. Erythromycin Stearate [usp:ban:jan]
34. Chembl1200510
35. Chebi:34742
36. Hms501d19
37. Erythromycin Stearate [mi]
38. Erythromycin Stearate/ >550ug/mg
39. Hms3264b08
40. Pharmakon1600-01500281
41. Erythromycin Stearate (jp17/usp)
42. Erythromycin Stearate [jan]
43. Erythromycin Stearate [hsdb]
44. Ccg-39117
45. Erythromycin Stearate [vandf]
46. Mfcd00084690
47. Nsc756747
48. Erythromycin Stearate [mart.]
49. Erythromycin Stearate [usp-rs]
50. Erythromycin Stearate [who-dd]
51. Erythromycin Stearate [who-ip]
52. Nsc 756747
53. Ncgc00180891-01
54. Erythromycin Stearate [orange Book]
55. Sbi-0207065.p001
56. Erythromycin Stearate [usp Impurity]
57. Hy-108875
58. Cs-0031206
59. Erythromycin Stearate [usp Monograph]
60. Erythromycini Stearas [who-ip Latin]
61. D02184
62. Erythromycin Stearate For Impurity S Identification
63. Sr-01000872741
64. Sr-01000872741-1
65. W-104851
66. Q27283244
67. Erythromycin Stearate, Antibiotic For Culture Media Use Only
Molecular Weight | 1018.4 g/mol |
---|---|
Molecular Formula | C55H103NO15 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 23 |
Exact Mass | 1017.73277158 g/mol |
Monoisotopic Mass | 1017.73277158 g/mol |
Topological Polar Surface Area | 231 Ų |
Heavy Atom Count | 71 |
Formal Charge | 0 |
Complexity | 1380 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Erythrocin stearate |
Drug Label | ERYTHROCIN STEARATE Filmtab tablets (erythromycin stearate tablets, USP) are an antibacterial product containing the stearate salt of erythromycin in a unique film coating.Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly... |
Active Ingredient | Erythromycin stearate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 250mg base |
Market Status | Prescription |
Company | Arbor Pharms |
2 of 2 | |
---|---|
Drug Name | Erythrocin stearate |
Drug Label | ERYTHROCIN STEARATE Filmtab tablets (erythromycin stearate tablets, USP) are an antibacterial product containing the stearate salt of erythromycin in a unique film coating.Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly... |
Active Ingredient | Erythromycin stearate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 250mg base |
Market Status | Prescription |
Company | Arbor Pharms |
ITS ACTIONS & USES ARE IDENTICAL TO THOSE OF ERYTHROMYCIN.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1124
ERYTHROMYCIN MAY BE USEFUL FOR DISSEMINATED GONOCOCCAL DISEASE IN PREGNANT PT WHO IS ALLERGIC TO PENICILLIN... 13 PT...TREATED WITH 500 MG OF ERYTHROMYCIN... STEARATE, GIVEN ORALLY EVERY 6 HR FOR 5 DAYS, SHOWED RAPID CLINICAL & BACTERIOLOGICAL RESPONSES.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1225
ANTIBACTERIAL AGENT
MEDICATION (VET): ANTIBACTERIAL AGENT
...ERYTHROMYCIN & ITS DERIV SELDOM CAUSE SERIOUS ADVERSE REACTIONS.
American Medical Association, AMA Department of Drugs. AMA Drug Evaluations. 4th ed. Chicago: American Medical Association, 1980., p. 1258
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
PEAK CONCN IN PLASMA...0.3-0.5 UG/ML 4 HR AFTER ORAL ADMIN OF 250 MG OF BASE & ARE 0.3-1.9 UG/ML AFTER...500-MG TABLET. VARIOUS ESTERS OF ERYTHROMYCIN HAVE BEEN PREPARED TO...IMPROVE STABILITY & FACILITATE ABSORPTION. ...CONCN OF ERYTHROMYCIN IN PLASMA ARE LITTLE DIFFERENT IF STEARATE IS GIVEN ORALLY.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
...DIFFUSES READILY INTO INTRACELLULAR FLUIDS, & ANTIBACTERIAL ACTIVITY... ACHIEVED AT...ALL SITES EXCEPT BRAIN & CSF. ...ONE OF FEW ANTIBIOTICS THAT PENETRATES INTO PROSTATIC FLUID, CONCN ARE APPROX 40% OF...PLASMA. EXTENT OF BINDING...TO PLASMA PROTEINS VARIES...PROBABLY EXCEEDS 70% IN ALL.../FORMS OF DRUG/. /ERYTHROMYCIN/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
ERYTHROMYCIN BASE IS ADEQUATELY ABSORBED FROM UPPER PART OF SMALL INTESTINE; IT IS INACTIVATED BY GASTRIC JUICE... FOOD IN STOMACH DELAYS ITS ULTIMATE ABSORPTION. /ERYTHROMYCIN/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
ERYTHROMYCIN TRAVERSES PLACENTAL BARRIER; & CONCN OF DRUG IN FETAL PLASMA ARE ABOUT 5-20% OF THOSE IN MATERNAL CIRCULATION. /ERYTHROMYCIN/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
For more Absorption, Distribution and Excretion (Complete) data for ERYTHROMYCIN STEARATE (11 total), please visit the HSDB record page.
IT IS HYDROLYZED IN SMALL INTESTINE & IN TISSUES TO YIELD ERYTHROMYCIN.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1124
...INHIBIT PROTEIN SYNTH BY BINDING TO 50 S RIBOSOMAL SUBUNITS OF SENSITIVE MICROORGANISMS. ... ASSOC BETWEEN ERYTHROMYCIN & RIBOSOME IS REVERSIBLE BUT TAKES PLACE ONLY WHEN 50 S SUBUNIT IS FREE FROM TRNA MOLECULES BEARING NASCENT PEPTIDE CHAINS. PRODN...OF HIGHLY POLYMERIZED HOMOPEPTIDES IS SUPPRESSED. /ERYTHROMYCIN/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
THE NONIONIZED FORM OF THE DRUG IS CONSIDERABLY MORE PERMEABLE TO CELLS, & THIS PROBABLY EXPLAINS INCREASED ANTIMICROBIAL ACTIVITY THAT IS OBSERVED AT ALKALINE PH. /ERYTHROMYCIN/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Erythromycin Stearate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromycin Stearate, including repackagers and relabelers. The FDA regulates Erythromycin Stearate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromycin Stearate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Erythromycin Stearate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Erythromycin Stearate supplier is an individual or a company that provides Erythromycin Stearate active pharmaceutical ingredient (API) or Erythromycin Stearate finished formulations upon request. The Erythromycin Stearate suppliers may include Erythromycin Stearate API manufacturers, exporters, distributors and traders.
click here to find a list of Erythromycin Stearate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Erythromycin Stearate DMF (Drug Master File) is a document detailing the whole manufacturing process of Erythromycin Stearate active pharmaceutical ingredient (API) in detail. Different forms of Erythromycin Stearate DMFs exist exist since differing nations have different regulations, such as Erythromycin Stearate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Erythromycin Stearate DMF submitted to regulatory agencies in the US is known as a USDMF. Erythromycin Stearate USDMF includes data on Erythromycin Stearate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Erythromycin Stearate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Erythromycin Stearate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Erythromycin Stearate Drug Master File in Japan (Erythromycin Stearate JDMF) empowers Erythromycin Stearate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Erythromycin Stearate JDMF during the approval evaluation for pharmaceutical products. At the time of Erythromycin Stearate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Erythromycin Stearate suppliers with JDMF on PharmaCompass.
A Erythromycin Stearate CEP of the European Pharmacopoeia monograph is often referred to as a Erythromycin Stearate Certificate of Suitability (COS). The purpose of a Erythromycin Stearate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Erythromycin Stearate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Erythromycin Stearate to their clients by showing that a Erythromycin Stearate CEP has been issued for it. The manufacturer submits a Erythromycin Stearate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Erythromycin Stearate CEP holder for the record. Additionally, the data presented in the Erythromycin Stearate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Erythromycin Stearate DMF.
A Erythromycin Stearate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Erythromycin Stearate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Erythromycin Stearate suppliers with CEP (COS) on PharmaCompass.
A Erythromycin Stearate written confirmation (Erythromycin Stearate WC) is an official document issued by a regulatory agency to a Erythromycin Stearate manufacturer, verifying that the manufacturing facility of a Erythromycin Stearate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Erythromycin Stearate APIs or Erythromycin Stearate finished pharmaceutical products to another nation, regulatory agencies frequently require a Erythromycin Stearate WC (written confirmation) as part of the regulatory process.
click here to find a list of Erythromycin Stearate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Erythromycin Stearate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Erythromycin Stearate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Erythromycin Stearate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Erythromycin Stearate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Erythromycin Stearate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Erythromycin Stearate suppliers with NDC on PharmaCompass.
Erythromycin Stearate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Erythromycin Stearate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Erythromycin Stearate GMP manufacturer or Erythromycin Stearate GMP API supplier for your needs.
A Erythromycin Stearate CoA (Certificate of Analysis) is a formal document that attests to Erythromycin Stearate's compliance with Erythromycin Stearate specifications and serves as a tool for batch-level quality control.
Erythromycin Stearate CoA mostly includes findings from lab analyses of a specific batch. For each Erythromycin Stearate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Erythromycin Stearate may be tested according to a variety of international standards, such as European Pharmacopoeia (Erythromycin Stearate EP), Erythromycin Stearate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erythromycin Stearate USP).
LOOKING FOR A SUPPLIER?